timothy sykes logo

Stock News

Soleno Therapeutics Surges Past Q3 Forecasts, Revenue Hits High

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 11/11/2025, 11:33 am ET 11/11/2025, 11:33 am ET | 5 min 5 min read
Soleno Therapeutics Surges Past Q3 Forecasts, Revenue Hits High Thumbnail

Soleno Therapeutics Inc.’s stocks have been trading up by 7.75 percent following promising news of FDA designation for their treatment.

Candlestick Chart

Live Update At 11:33:01 EST: On Tuesday, November 11, 2025 Soleno Therapeutics Inc. stock [NASDAQ: SLNO] is trending up by 7.75%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

The financial terrain for Soleno Therapeutics Inc. took an impressive turn in the third quarter of 2025, with striking results that have stirred up conversations in the investment world. At first glance, the company’s revenue of $66M marks a significant crescendo from the forecasted $48.09M. Dipping into their financial success, Soleno’s headline drug VYKAT XR has made waves, contributing to a reported net income of $26M. This achievement underlines a remarkable transition from previous financial hurdles, demonstrating a robust market position.

Analyzing the stock’s performance, it exhibited a dynamic journey over the past days, with highs of $50.78 and lows of around $47.71, reflecting investor reactions and market fluctuations. Despite the slightly uneasy 22% drop in after-hours trading, the resilience of Soleno’s financials is undeniable, driven by strategic sales and operational achievements.

Investor Confidence and Market Reactions

Amidst mixed market sentiments, investor confidence appears buoyant, thanks to Soleno’s latest financial feats. The surge in revenue growth underscores the potential embedded in their strategic product offerings. The triumph of VYKAT XR, notably, signals hope for substantial market opportunities, even as skeptical advisories from investment analysts present cautious optimism.

Significantly, Wells Fargo’s decision to downgrade SLNO’s price target from $123 to $106 captures the balance between optimism for Vykat XR and broader market realities. Despite this, maintaining an “Overweight” rating suggests an expected upward journey, fueled by product potential rather than immediate speculative gains.

More Breaking News

Meanwhile, the Betaville blog reignites M&A chatter, compounding growing speculation and interest in Soleno as a formidable player within the biopharmaceutical arena. Shareholders and potential investors watch keenly, drawn by prospects of strategic partnerships and expansions.

Industry Dynamics and Competitive Edge

Flipping through the pages of the industry narrative, Soleno Therapeutics climbs the ladder bolstered by its keen market insights and agility. Stepping back, the backdrop paints an intricate picture: an evolving market landscape encountering potential buy-out rumors, regulatory discussions, and strategic engagements.

In this multifaceted tale, SLNO lies centric, navigating through a sea of opportunities and thin market currents. The company capitalizes on synergies in its niche, promoting VYKAT XR as a cornerstone product addressing specific therapeutic needs in patients with Prader-Willi Syndrome.

Complementing its stronghold, the recent inductance of Mark Hahn into its Audit Committee brings seasoned finance acumen onto the board, a calculated maneuver auguring well for governance and strategic decision-making.

Conclusion

In summary, Soleno Therapeutics stands at a fascinating crossroad. The quarterly financial performance emboldens its market narrative, proving its resilience and innovative mettle amidst broader market uncertainties. The prevalent discourse around potential mergers and acquisitions adds layers to its ongoing journey, with shareholders and the market eyeing possible strategic pivots or partnerships. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” This mantra rings particularly true for Soleno, as it navigates its current landscape.

While the stock landscape remains as volatile as ever, Soleno’s careful balancing act–between delivering immediate growth and planning for long-term gains–peaks trader curiosity. As the coming weeks unfold, stakeholders are poised for market responses that will shape the narrative for both SLNO and the wider biopharmaceutical market. The anticipatory climate continues, promising engaging stories and pivotal market maneuvers.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”